Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia

Blood

Volumn 116, Issue 14, 2010, Pages 2411-2419

  Cooley, Sarah ^a   Weisdorf, Daniel J ^a   Guethlein, Lisbeth A ^b   Klein, John P ^c   Wang, Tao ^c   Le, Chap T ^d   Marsh, Steven G E ^e   Geraghty, Daniel ^f   Spellman, Stephen ^g   Haagenson, Michael D ^h   Ladner, Martha ⁱ   Trachtenberg, Elizabeth ⁱ   Parham, Peter ^b   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f Fred Hutchinson Cancer Research Center   (United States)

^g NATIONAL MARROW DONOR PROGRAM   (United States)

^h CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

ⁱ CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CHILD; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DONOR SELECTION; GENOTYPE; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HOMOZYGOSITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN MOTIF; RECEPTOR GENE; RELAPSE; RISK FACTOR; SCHOOL CHILD;

EID: 77957734984     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-283051     Document Type: Article

References (50)

1. Appelbaum FR. Hematopoietic cell transplantation for adult acute myeloid leukemia. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, eds. Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation. 4th ed. Malden, MA: Blackwell Publishing; 2009:761.
2. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25(27):4246-4254.
3. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349-2361.
4. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576-4583. (Pubitemid 351377826)
5. Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility- complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med. 2001;345(25):1794-1800.
6. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98(7):2043-2051.
7. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-469.
8. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med. 1989;320(26):1731-1735. (Pubitemid 19163129)
9. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237-244.
10. Shum BP, Flodin LR, Muir DG, et al. Conservation and variation in human and common chimpanzee CD94 and NKG2 genes. J Immunol. 2002;168(1):240-252.
11. Wagtmann N, Biassoni R, Cantoni C, et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity. 1995;2(5):439-449.
12. Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7(6):753-763. (Pubitemid 28064889)
13. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science. 1995;268(5209):405-408.
14. Valiante NM, Uhrberg M, Shilling HG, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7(6):739-751. (Pubitemid 28064888)
15. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100. (Pubitemid 34229476)
16. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3):814-819. (Pubitemid 36917769)
17. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood. 2002;100(10):3825-3827.
18. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5(3):201-214. (Pubitemid 40364822)
19. Shilling H, Young N, Guethlein LA, et al. Genetic control of human NK cell repertoire. J Immunol. 2002;169:239-247. (Pubitemid 34686141)
20. Wilson MJ, Torkar M, Haude A, et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci U S A. 2000;97(9):4778-4783. (Pubitemid 30238634)
21. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113(3):726-732.
22. Stringaris K, Adams S, Uribe M, et al. Donor KIR genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukaemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukaemia but not other haematological malignancies. Biol Blood Marrow Transplant. 2010;16(9):1257-1264.
23. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2010;16(4):533-542.
24. Houtchens KA, Nichols RJ, Ladner MB, et al. High-throughput killer cell immunoglobulin-like receptor genotyping by MALDI-TOF mass spectrometry with discovery of novel alleles. Immunogenetics. 2007;59(7):525-537.
25. McQueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol. 2007;68(5):309-323. (Pubitemid 46616984)
26. Yawata M, Yawata N, Abi-Rached L, Parham P. Variation within the human killer cell immunoglobulin-like receptor (KIR) gene family. Crit Rev Immunol. 22(5-6):463-482, 2002. (Pubitemid 36548955)
27. Martin AM, Kulski JK, Gaudieri S, et al. Comparative genomic analysis, diversity and evolution of two KIR haplotypes A and B. Gene. 2004;335:121-131. (Pubitemid 38759758)
28. Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fixed point in time. Stat Med. 2007;26(24):4505-4519. (Pubitemid 47534694)
29. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York, NY: Springer Verlag; 2003.
30. Ringden O, Pavletic SZ, Anasetti C, et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009;113(13):3110-3118.
31. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol. 1998;161(2):571-577. (Pubitemid 28323516)
32. Stewart CA, Laugier-Anfossi F, Vely F, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005;102(37):13224-13229. (Pubitemid 41325005)
33. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol. 2008;180(6):3969-3979.
34. Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood. 2008;112(6):2369-2380.
35. Brodin P, Karre K, Hoglund P. NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol. 2009;30(4):143-149.
36. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305(5685):872- 874.
37. Hou L, Chen M, Steiner NK, et al. Seventeen novel alleles add to the already extensive KIR3DL3 diversity. Tissue Antigens. 2007;70(6):449-454. (Pubitemid 350075783)
38. Jones DC, Hiby SE, Moffett A, Trowsdale J, Young NT. Nature of allelic sequence polymorphism at the KIR3DL3 locus. Immunogenetics. 2006;58(8):614-627. (Pubitemid 44100410)
39. Lundqvist A, McCoy JP, Samsel L, Childs R. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood. 2007;109(8):3603-3606. (Pubitemid 46572556)
40. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002;20:323-370.
41. Siefer AK, Longo DL, Harrison CL, Reynolds CW, Murphy WJ. Activated natural killer cells and interleukin-2 promote granulocytic and megakaryocytic reconstitution after syngeneic bone marrow transplantation in mice. Blood. 1993;82(8):2577-2584.
42. Hsu KC, Gooley T, Malkki M, et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2006;12(8):828-836. (Pubitemid 44070671)
43. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172(1):644-650. (Pubitemid 38020523)
44. Bishara A, De Santis D, Witt CC, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens. 2004;63(3):204-211. (Pubitemid 38297254)
45. Lowe EJ, Turner V, Handgretinger R, et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-nonidentical paediatric bone marrow transplantation. Br J Haematol. 2003;123(2):323-326. (Pubitemid 37305068)
46. Farag SS, Bacigalupo A, Eapen M, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant. 2006;12(8):876-884. (Pubitemid 44070674)
47. Chen C, Busson M, Rocha V, et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell-depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant. 2006;38(6):437-444. (Pubitemid 44340375)
48. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105(12):4878-4884. (Pubitemid 40807317)
49. Cook MA, Milligan DW, Fegan CD, et al. The impact of donor KIR and patient HLA-C genotypes on outcome after HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood. 2004;103(4):1521-1526.
50. Venstrom JM, Gooley TA, Spellman S, et al. Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood. 2010;115(15):3162-3165.